#China #Shenzhen #Genomics #MGI Tech #DNBSEQ-T7+

MGI Tech Unveils DNBSEQ-T7+: A Game-Changer in Genomic Sequencing

In September 2025, MGI Tech Co., Ltd., renowned for its innovation in life sciences, made waves in the field of genomics with the launch of its latest high-throughput sequencer, the DNBSEQ-T7+. Designed specifically for large-scale genomic research, this groundbreaking technology promises to deliver a staggering output of over 14 terabases (Tb) of data in just 24 hours, marking a significant leap forward from its predecessor, the DNBSEQ-T7.

Revolutionizing High-Throughput Sequencing

The DNBSEQ-T7+ is equipped with MGI’s proprietary DNBSEQ™ technology, which is integrated with next-generation fluidics and optics combined with advanced bioinformatics. The result is an intuitive system that is faster, smarter, and more versatile than ever before.

This innovative machine supports between 1 to 4 flow cells per run, allowing it to adjust seamlessly to the project scale. It automates every step of the sequencing process, from DNB preparation to bioinformatics analysis, providing researchers with an end-to-end automated workflow.

Key Features and Technical Highlights

• - Throughput: Exceeding 14 Tb/day, significantly higher than the 7 Tb/day capability of the original DNBSEQ-T7.
• - Annual Capacity: Capable of processing up to 35,000 whole-genome sequencing (WGS) tasks annually.
• - Accuracy: Consistently achieves greater than 90% Q40 quality scores, validated through extensive beta testing conducted by leading laboratories.
• - Speed: Processes PE150 reads in under 24 hours, facilitating quick results for researchers.
• - Flexibility: Configurable for both mid-scale and large-scale studies, adapting to user needs.
• - Size Efficiency: Requires only 1 square meter of space, making it compact in design yet powerful in function.
• - Integrated Workflow: Combines hardware and software architecture that eliminates manual preparation steps, enhancing efficiency.
• - Reduced Energy Consumption: The system is designed to minimize energy usage, ensuring that over 90% of transport links and specific reagents do not necessitate a cold chain, thus lowering operational costs.

With this suite of capabilities, the DNBSEQ-T7+ enables the rapid sequencing of 144 human genomes in just a single day. This advancement is poised to facilitate breakthroughs in various areas, including cancer genomics, rare disease research, and precision medicine.

Building on the T7 Legacy

The launch of the T7+ continues the legacy of the original DNBSEQ-T7, which was a significant milestone when it debuted in 2018 and set a new standard for throughput and accessibility in high-throughput sequencing technologies. With over 400 units currently in operation across more than 200 prominent institutions worldwide, including major genomic initiatives like Thailand's Genomics Thailand Initiative and Brazil's expansive genomic sequencing project, the T series has reshaped the landscape of genomic research.

As the demand for more efficient genomic sequencing rises, MGI Tech has responded with the T7+, striving to deliver unmatched speed, scalability, and superior performance necessary for the evolving challenges in clinical research and large-scale studies.

Enhancing User Experience

The T7+ successfully navigates the challenges researchers face—trading off speed for capacity and usability for cost. By integrating a user-friendly, smartphone-like interface with 7-in-1 hardware, the T7+ streamlines the sequencing process, making it accessible even for those new to genomic technology. This instrument supports a variety of multi-omics applications—including spatial omics, single-cell studies, and methylation analyses—enabling concurrent data acquisition across various studies.

Duncan Yu, President of MGI Tech, emphasizes the significance of the T7+, stating, “The T7+ is more than just a sequencer—it bridges the gap between scientific discovery and real-world health applications. With enhanced throughput and greater accuracy, it empowers scientists to tackle larger questions and yield faster insights. Each sequenced genome has the potential to enhance rare disease diagnostics, guide precision oncology strategies, and inform public health policies on a broad scale.”

Early implementations of the T7+ are already underway in population-scale studies. Its ability to provide short-read power combined with cyclone long-read data is enhancing the detection of structural variants and aiding in the analysis of rare diseases. Furthermore, the synergy between the T7+ and long-read platforms for single-cell explorations opens new avenues for understanding genetic diversity and cellular complexity.

The T7+ is now available for order, and international shipments are set to commence in late 2025, paving the way for a new era in genomic research and innovation.